Author: Ravi Shankar

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH THE TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW. FOR FURTHER INFORMATION, PLEASE SEE SECTION ENTITLED “IMPORTANT INFORMATION” BELOW.

Preliminary result of the subsequent offer period of S-Bank Plc’s voluntary recommended public cash tender offer for all the shares in Oma Savings Bank Plc

OMA SAVINGS BANK PLC        STOCK EXCHANGE RELEASE      23 October 2026 at 14:05 (EEST)

On 9 July 2026, S-Bank Plc (“S-Bank” or the “Offeror“), announced a voluntary recommended public cash tender offer for all the issued and outstanding shares in Oma Savings Bank Plc (“Oma Savings Bank“) that are not held by Oma Savings Bank or its subsidiaries (the “Shares” or, individually, a “Share“) (the “Tender Offer“). The Offeror has published a tender offer document, dated 16 July 2026, concerning the Tender Offer and the supplements to the tender offer document, dated 14 August 2026, 31 August 2026, 7 September 2026 and 16 September 2026. The offer period under the Tender Offer commenced on 17 July 2026 at 9:30 a.m. (Finnish time) and expired on 25 September 2026 at 4:00 p.m. (Finnish time). On 1 October 2026 at 9:30 a.m. (Finnish time), the Offeror commenced a subsequent offer period (the “Subsequent Offer Period“) in accordance with the terms and conditions of the Tender Offer, which expired on 22 October 2026 at 4:00 p.m. (Finnish time).

Based on the preliminary result of the Subsequent Offer Period, the 162,531 Shares validly tendered during the Subsequent Offer Period represent approximately 0.49 percent of all issued and outstanding shares and votes in Oma Savings Bank (excluding treasury shares). The Shares tendered during the Subsequent Offer Period, together with the Shares tendered during the initial offer period and any Shares otherwise acquired by the Offeror, represent approximately 97.32 percent of all issued and outstanding shares and votes in Oma Savings Bank (excluding treasury shares).

The Offeror will confirm and announce the final result of the Subsequent Offer Period on or about 26 October 2026. The tender offer consideration for the Shares validly tendered during the Subsequent Offer Period is expected to be paid to the shareholders on or about 2 November 2026. The actual timing of the receipt of the tender offer consideration will depend on the schedules for payment transactions between financial institutions.

The Offeror has reserved the right to acquire Shares on or after the date of this release in public trading on Nasdaq Helsinki Ltd (“Nasdaq Helsinki“) or otherwise to the extent permitted by applicable laws and regulations.

ADVISERS

The Offeror has appointed PricewaterhouseCoopers Oy as lead financial adviser, Danske Bank A/S, Finland Branch as arranger of the tender offer, Borenius Attorneys Ltd as legal adviser, and IR Partners Oy as communication advisor in connection with the Tender Offer. Oma Savings Bank has appointed EY Advisory Oy as financial adviser, Krogerus Attorneys Ltd as legal adviser and Rud Pedersen Finland Ltd as communication advisor in connection with the Tender Offer.

Additional information:

Oma Savings Bank Plc

Karri Alameri, CEO, interview requests via Chief Communications Officer

Pirjetta Soikkeli, Chief Communications Officer, tel. +358 40 7500 093, pirjetta.soikkeli@omasp.fi

www.omasp.fi

S-Bank Plc

Riikka Laine-Tolonen, CEO, interview requests via communications

Tiina Nurmi, Chief Communications Officer, tel. +358 10 768 1689, tiina.2.nurmi@s-pankki.fi

S-Bank Communications, tel. +358 10 767 9300, viestinta@s-pankki.fi

Information regarding the Tender Offer is available at www.s-pankki.fi/tenderoffer.

ABOUT OMA SAVINGS BANK

Oma Savings Bank is a well-capitalised and profitable Finnish bank that serves over 200,000 personal and corporate customers through 48 branches across Finland and digital channels with approximately 600 experts. Oma Savings Bank focuses primarily on retail banking and offers its customers a diverse range of banking services both through its own balance sheet and by intermediating products of its cooperation partners, such as credit, investment and loan protection products. Oma Savings Bank also engages in mortgage banking operations. Oma Savings Bank’s key objective is a first-class customer experience through personal service and easy accessibility in both digital and traditional channels. The Shares of Oma Savings Bank are listed on the regulated market maintained by Nasdaq Helsinki.

ABOUT S-BANK

S-Bank is a well-capitalised bank and part of the domestic S Group. S-Bank was created as a bank for co-op members with the mission of ensuring that everyone has the possibility of a little more wealth. S-Bank offers its customers banking, financing and wealth management services and engages in mortgage banking operations. At the end of 2025, S-Bank had more than 3.4 million customers, of which 858,000 were active customers. S-Bank’s strategy is to grow the number of active customers and the share of customers who consolidate their banking activities with S-Bank, and to offer superior ease and benefits through a service model that combines digital and personal service. S-Bank employs approximately 1,200 experts.

IMPORTANT INFORMATION

THIS RELEASE MAY NOT BE RELEASED OR OTHERWISE DISTRIBUTED, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH THE TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW.

THIS RELEASE IS NOT A TENDER OFFER DOCUMENT AND AS SUCH DOES NOT CONSTITUTE AN OFFER OR INVITATION TO MAKE A SALES OFFER. IN PARTICULAR, THIS RELEASE IS NOT AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY ANY SECURITIES DESCRIBED HEREIN, AND IS NOT AN EXTENSION OF THE TENDER OFFER IN AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA. INVESTORS SHALL ACCEPT THE TENDER OFFER FOR THE SHARES ONLY ON THE BASIS OF THE INFORMATION PROVIDED IN A TENDER OFFER DOCUMENT. OFFERS WILL NOT BE MADE DIRECTLY OR INDIRECTLY IN ANY JURISDICTION WHERE EITHER AN OFFER OR PARTICIPATION THEREIN IS PROHIBITED BY APPLICABLE LAW OR WHERE ANY TENDER OFFER DOCUMENT OR REGISTRATION OR OTHER REQUIREMENTS WOULD APPLY IN ADDITION TO THOSE UNDERTAKEN IN FINLAND.

THE TENDER OFFER IS NOT BEING MADE DIRECTLY OR INDIRECTLY IN ANY JURISDICTION WHERE PROHIBITED BY APPLICABLE LAW AND, WHEN PUBLISHED, THE TENDER OFFER DOCUMENT AND RELATED ACCEPTANCE FORMS WILL NOT AND MAY NOT BE DISTRIBUTED, FORWARDED OR TRANSMITTED INTO OR FROM ANY JURISDICTION WHERE PROHIBITED BY APPLICABLE LAWS OR REGULATIONS. IN PARTICULAR, THE TENDER OFFER IS NOT BEING MADE, DIRECTLY OR INDIRECTLY, IN OR INTO, OR BY USE OF THE POSTAL SERVICE OF, OR BY ANY MEANS OR INSTRUMENTALITY (INCLUDING, WITHOUT LIMITATION, FACSIMILE TRANSMISSION, TELEX, TELEPHONE OR THE INTERNET) OF INTERSTATE OR FOREIGN COMMERCE OF, OR ANY FACILITIES OF A NATIONAL SECURITIES EXCHANGE OF, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA. THE TENDER OFFER CANNOT BE ACCEPTED, DIRECTLY OR INDIRECTLY, BY ANY SUCH USE, MEANS OR INSTRUMENTALITY OR FROM WITHIN, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA AND ANY PURPORTED ACCEPTANCE OF THE TENDER OFFER RESULTING DIRECTLY OR INDIRECTLY FROM A VIOLATION OF THESE RESTRICTIONS WILL BE INVALID.

THIS STOCK EXCHANGE RELEASE HAS BEEN PREPARED IN COMPLIANCE WITH FINNISH LAW, THE RULES OF NASDAQ HELSINKI AND THE HELSINKI TAKEOVER CODE AND THE INFORMATION DISCLOSED MAY NOT BE THE SAME AS THAT WHICH WOULD HAVE BEEN DISCLOSED IF THIS ANNOUNCEMENT HAD BEEN PREPARED IN ACCORDANCE WITH THE LAWS OF JURISDICTIONS OUTSIDE OF FINLAND.

Information for shareholders of Oma Savings Bank in the United States

Shareholders of Oma Savings Bank in the United States are advised that the Shares are not listed on a U.S. securities exchange and that Oma Savings Bank is not subject to the periodic reporting requirements of the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act“), and is not required to, and does not, file any reports with the U.S. Securities and Exchange Commission (the “SEC“) thereunder.

The Tender Offer will be made for the issued and outstanding shares of Oma Savings Bank, which is domiciled in Finland, and is subject to Finnish disclosure and procedural requirements. The Tender Offer is made in the United States pursuant to Section 14(e) and Regulation 14E under the Exchange Act, subject to the exemption provided under Rule 14d-1(c) under the Exchange Act, for a “Tier I” tender offer, and otherwise in accordance with the disclosure and procedural requirements of Finnish law, including with respect to the Tender Offer timetable, settlement procedures, withdrawal, waiver of conditions and timing of payments, which are different from those of the United States. In particular, the financial information included in this announcement has been prepared in accordance with applicable accounting standards in Finland, which may not be comparable to the financial statements or financial information of U.S. companies.

You should note that the Offeror’s ability to waive the conditions to the Tender Offer (both during and after the end of the acceptance period) and the shareholders’ ability to withdraw their acceptances, are not the same under a tender offer governed by Finnish law as under a tender offer governed by U.S. law. U.S. shareholders are encouraged to consult with their own advisors regarding the Tender Offer. In particular, the Offeror may waive conditions to the Tender Offer without offering withdrawal rights, to the extent not required by applicable law.

The Tender Offer is made to Oma Savings Bank’s shareholders resident in the United States on the same terms and conditions as those made to all other shareholders of Oma Savings Bank to whom an offer is made. Any informational documents, including this announcement, are being disseminated to U.S. shareholders on a basis comparable to the method that such documents are provided to Oma Savings Bank’s other shareholders.

To the extent permissible under applicable law or regulations, the Offeror and its affiliates or its brokers and its brokers’ affiliates (acting as agents for the Offeror or its affiliates, as applicable) may from time to time after the date of this stock exchange release and during the pendency of the Tender Offer, and other than pursuant to the Tender Offer, directly or indirectly purchase or arrange to purchase Shares or any securities that are convertible into, exchangeable for or exercisable for Shares. These purchases may occur either in the open market at prevailing prices or in private transactions at negotiated prices. To the extent information about such purchases or arrangements to purchase is made public in Finland, such information will be disclosed by means of a press release or other means reasonably calculated to inform U.S. shareholders of Oma Savings Bank of such information. In addition, the financial advisers to the Offeror may also engage in ordinary course trading activities in securities of Oma Savings Bank, which may include purchases or arrangements to purchase such securities. To the extent required in Finland, any information about such purchases will be made public in Finland in the manner required by Finnish law.

Neither the SEC nor any U.S. state securities commission has approved or disapproved the Tender Offer, passed upon the merits or fairness of the Tender Offer, or passed any comment upon the adequacy, accuracy or completeness of the disclosure in relation to the Tender Offer. Any representation to the contrary is a criminal offence in the United States.

The receipt of cash pursuant to the Tender Offer by a U.S. holder of Shares may be a taxable transaction for U.S. federal income tax purposes and under applicable U.S. state and local, as well as foreign and other, tax laws. Each holder of Shares is urged to consult its independent professional advisers immediately regarding the tax and other consequences of accepting the Tender Offer.

To the extent the Tender Offer is subject to U.S. securities laws, those laws only apply to U.S. holders of Shares and will not give rise to claims on the part of any other person. It may be difficult for Oma Savings Bank’s shareholders to enforce their rights and any claims they may have arising under the U.S. federal securities laws, since the Offeror and Oma Savings Bank are located in non-U.S. jurisdictions and some or all of their respective officers and directors may be residents of non-U.S. jurisdictions. Oma Savings Bank shareholders may not be able to sue the Offeror or Oma Savings Bank or their respective officers or directors in a non-U.S. court for violations of the U.S. federal securities laws. It may be difficult to compel the Offeror and Oma Savings Bank and their respective affiliates to subject themselves to a U.S. court’s judgment.

Forward-looking statements

This release contains statements that, to the extent they are not historical facts, constitute “forward-looking statements”. Forward-looking statements include statements concerning plans, expectations, projections, objectives, targets, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs, plans or intentions relating to acquisitions, competitive strengths and weaknesses, plans or goals relating to financial position, future operations and development, business strategy and the trends in the industries and the political and legal environment and other information that is not historical information. In some instances, they can be identified by the use of forward-looking terminology, including the terms “believes”, “intends”, “may”, “will” or “should” or, in each case, their negative or variations on comparable terminology. By their very nature, forward-looking statements involve inherent risks, uncertainties and assumptions, both general and specific, and risks exist that the predictions, forecasts, projections and other forward-looking statements will not be achieved. Given these risks, uncertainties and assumptions, investors are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements contained herein speak only as at the date of this release.

Disclaimer

PricewaterhouseCoopers Oy is acting as financial adviser to the Offeror and no-one else in connection with this announcement. Neither PricewaterhouseCoopers Oy nor its affiliates, nor their respective partners, directors, officers, employees or agents are responsible to anyone other than the Offeror for providing the protections afforded to clients of PricewaterhouseCoopers Oy or for providing advice in connection with any matters referred to in this announcement.

Danske Bank A/S is authorised under Danish banking law. It is subject to supervision by the Danish Financial Supervisory Authority. Danske Bank A/S is a private, limited liability company incorporated in Denmark with its head office in Copenhagen where it is registered in the Danish Commercial Register under number 61126228.

Danske Bank A/S (acting via its Finland Branch) is acting as arranger for the benefit of the Offeror and no other person in connection with these materials or their contents. Danske Bank A/S will not be responsible to any person other than the Offeror for providing any of the protections afforded to clients of Danske Bank A/S, nor for providing any advice in relation to any matter referred to in these materials. Without limiting a person’s liability for fraud, Danske Bank A/S, nor any of its affiliates nor any of its respective directors, officers, representatives, employees, advisers or agents shall have any liability to any other person (including, without limitation, any recipient) in connection with the Tender Offer.

EY Advisory Oy is acting exclusively for Oma Savings Bank Plc and no one else in connection with the Tender Offer and the matters set out in this announcement. Neither EY Advisory Oy nor its affiliates, nor their respective partners, directors, officers, employees or agents are responsible to anyone other than Oma Savings Bank for providing the protections afforded to clients of EY Advisory Oy, or for giving advice in connection with the Tender Offer or any matter or arrangement referred to in this announcement.

PONTE VEDRA, Fla., Oct. 23, 2026 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the third quarter 2026 before the start of trading on Friday, November 6, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET.

Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and archived webcast of the event will be available on the Company’s investor relations website at https://investors.treace.com/.

Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.

About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty^® 3D Bunion Correction^® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of surgeons and bunion patients, Treace offers its Adductoplasty^® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, two systems for minimally invasive osteotomy procedures, namely the Nanoplasty^® 3D Minimally Invasive Bunion Correction System and the Percuplasty^™ Percutaneous 3D Bunion Correction System, and the SpeedMTP^® System. Treace continues to expand its footprint in the marketplace by extending its SpeedPlate^® rapid compression implant platform to new applications, as well as providing surgeons with advanced digital solutions with its IntelliGuide^® patient specific, pre-op planning and cut guide technology. For more information, please visit www.treace.com.

To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.

Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940

Investors:
Gilmartin Group
Philip Trip Taylor
IR@treace.net

SHENZHEN, China, Oct. 23, 2026 (GLOBE NEWSWIRE) — Nexpu Ltd. (Nasdaq: DPU) (“Nexpu” or the “Company”) today announced that its subsidiary, Top Kingwin Technology INC, has launched a customizable music creation platform, branded as DPU (the “DPU Platform”), designed to help users create songs and instrumental tracks based on their own ideas, lyrics and preferred musical styles.

Short-form videos, social media and digital storytelling increasingly rely on music as part of everyday content creation. The DPU Platform integrates third-party AI technology with the Company’s proprietary AI models, including its DPU-related model, to offer users a platform for music creation, listening and sharing.

Turning Ideas into Personalized Music

DPU Platform offers two creation modes. In description mode, users enter a musical style and theme, with the option to generate instrumental music. In lyrics mode, users provide lyrics, select or customize a musical style, and enter a song title.

Users can preview generated tracks within the creation interface, edit titles and cover images, download selected works, and publish their music within the platform for other users to view.

These features allow users to experiment with different musical styles and develop tracks based on their own preferences for song ideas or other digital content.

Connecting Creation, Discovery and Sharing

Beyond music creation, DPU Platform provides discovery by musical style and tags, personal libraries for managing works, and account and membership management. Chinese- and English-language interfaces are available.

The platform’s membership and usage-credit framework provide a foundation for tiered services. Specific features, access and usage allowances are governed by the applicable membership terms. Commercial use of generated or uploaded content remains subject to platform terms, third-party licenses and applicable intellectual property requirements.

Expanding Nexpu’s Software Portfolio

The launch adds a customizable music application to Nexpu’s software portfolio through Top Kingwin Technology INC, reflecting the group’s continued development of software products for user applications.

Top Kingwin Technology INC intends to refine DPU Platform through user feedback and ongoing product development. Future enhancements and commercial expansion will depend on user demand, technical performance and applicable licensing requirements.

This press release contains forward-looking statements. Please see the “Safe Harbor Statement” below for additional information.

About Nexpu Ltd. (formerly known as Top KingWin Ltd)

Nexpu Ltd. (formerly known as Top KingWin Ltd) engages in the following business activities: (i) the sale of devices that support data collection and analysis; (ii) the sale of robots; and (iii) the development and operation of software products and platforms.

Safe Harbor Statement

This announcement contains forward-looking statements made under the “safe harbor” provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. These statements are based on management’s current expectations as of the date of this release and are subject to risks and uncertainties that could cause actual results to differ materially, including but not limited to: the DPU Platform is newly launched and may not perform as intended or achieve anticipated user adoption or commercial success; the platform’s functionality and performance may depend on third-party AI technologies, services and infrastructure; the Company may encounter technical challenges, intellectual property or licensing issues, or regulatory uncertainties in connection with the development, operation and commercialization of the platform; planned enhancements and future commercial expansion may not materialize as anticipated; and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

For further information, please contact:

Bonnie Zhang

Email: IR@tcjhgw.cn

NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Atari (Euronext Paris: ALATA; OTCQX: PONGF), an interactive entertainment company, has qualified to trade on the OTCQX® Best Market.

Atari begins trading today on OTCQX under the symbol “PONGF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

Atari is one of the most recognized and celebrated brands in the world. Their team is dedicated to honoring the legacy of the brand, and building upon its success so that Atari continues to be associated with fun for years to come.

Trading on the OTCQX Market offers companies efficient, cost-effective access to the U.S. capital markets. For companies listed on a qualified international exchange, streamlined market standards enable them to utilize their home market reporting to make their information available in the U.S. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws.

“Moving to OTCQX is an important milestone for Atari and a practical step that gives U.S. investors real-time quotes and more convenient access to Atari shares,” said Wade Rosen, Chairman and CEO of Atari.

“We are excited to welcome Atari to the OTCQX Market,” said Jonathan Dickson, VP, Head of EMEA at OTC Markets Group. “As one of the world’s most iconic consumer brands and interactive entertainment producers, Atari’s addition to OTCQX enhances U.S. investors’ ability to access global brands and strengthens the connection between European and U.S. capital markets.”

Trading in European securities on OTC Markets reached $97.45 billion in the third quarter of 2026, representing an 23.37% increase over Q3 2025. OTC Markets recorded $656.81 billion in total dollar volume in the first three quarters of the year. Europe ranked among the top home markets by trading volume during the quarter, highlighting sustained U.S. investor demand for internationally listed names.

About Atari
Atari is an interactive entertainment company and an iconic gaming industry brand that transcends generations and audiences. The company is globally recognized for its multi-platform, interactive entertainment and licensed products. Atari owns and/or manages a portfolio of more than 400 unique games and franchises, including world-renowned brands like Asteroids®, Centipede®, Missile Command®, Pong®, and RollerCoaster Tycoon®.

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our public markets: OTCQX® Best Market, OTCQB® Venture Market, OTCID™ Basic Market and Pink Limited™ Market. Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets.

OTC Link ATS, OTC Link ECN, OTC Link NQB, OTC Overnight® and MOON ATS® are each an SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com

NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced ACT Energy Technologies Ltd. (TSX: ACX; OTCQX: ACXAF), a provider of directional drilling services to oil and natural gas companies in Canada and the United States, has qualified to trade on the OTCQX® Best Market. ACT Energy Technologies Ltd. upgraded to OTCQX from the OTCQB® Venture Market.

ACT Energy Technologies Ltd. begins trading today on OTCQX under the symbol “ACXAF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

ACT Energy Technologies Ltd. is a trusted partner to North American energy companies requiring high-performance directional drilling, MWD and rotary steerable services, as well as in providing remote operations. ACT Energy Technologies Ltd. collaborates with customers to tailor their equipment and expertise to meet their specific technical downhole needs.

The OTCQX Market is designed for established, investor-focused U.S. and international companies. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. Graduating to the OTCQX Market from the OTCQB Market marks an important milestone for companies, enabling them to demonstrate their qualifications and build visibility among U.S. investors.

Trading in non-U.S. North American securities on OTC Markets reached $29.38B in the third quarter of 2026, representing an 84.22% increase over Q3 2025. OTC Markets recorded $203.47B in total dollar volume in Q3. North America ranked among the top home markets by trading volume during the quarter, highlighting sustained U.S. investor demand for internationally listed names.

About ACT Energy Technologies Ltd.
ACT Energy Technologies Ltd., together with its subsidiaries, provides directional drilling services to oil and natural gas companies in Canada and the United States. It offers remote directional and measurement-while-drilling (MWD), automated gamma, drilling optimization, and well planning and rotary steerable services. The company also offers mud motors, MWD technology solutions, rotary steerable systems, drilling motors and components, and downhole technology products. It is also involved in the operation of real-time operations centers that offer continuous monitoring, collaboration, and optimization services. It also provides equipment rental, training, maintenance, and repair services.

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our public markets: OTCQX® Best Market, OTCQB® Venture Market, OTCID™ Basic Market and Pink Limited™ Market. Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets.

OTC Link ATS, OTC Link ECN, OTC Link NQB, OTC Overnight® and MOON ATS® are each an SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com

Recognitions Reflect Strong Financial Performance and Continued Marketplace Growth

EL MONTE, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) — GigaCloud Technology Inc (Nasdaq: GCT) (“GigaCloud” or the “Company”), a pioneer of global end-to-end B2B technology solutions for large parcel merchandise, today announced it ranked No. 13 on Fortune’s Fastest Growing Companies™ 2026 list and No. 12 on TIME’s America’s Growth Leaders 2027 list.

The recognitions build on GigaCloud’s growing record of industry accolades, marking its second consecutive year in TIME’s U.S. growth ranking and following its inclusion on the magazine’s World’s Growth Leaders 2026 list. These distinctions reflect the Company’s continued expansion of its global B2B marketplace and execution of its long-term strategy.

“At a time when technological innovation is reshaping industries and creating new opportunities across the economy, we are especially honored to receive this recognition from both Fortune and TIME,” said Larry Wu, Founder and Chief Executive Officer of GigaCloud. “It is a meaningful acknowledgment of the progress we have made in an industry that plays a fundamental role in global commerce, and a reminder of the responsibility we have to help move it forward. We remain committed to delivering greater value and operational efficiency for the businesses we serve and accelerating the digital transformation of the global large-parcel supply chain.”

The complete Fortune Fastest Growing Companies 2026™ and TIME’s America’s Growth Leaders 2027 lists are available here and here, respectively.

About the Fortune Fastest Growing Companies List
Now in its 41^st year, the Fortune Fastest Growing Companies™ list recognizes publicly traded companies demonstrating strong growth across key financial measures. Companies are evaluated based on revenue growth, earnings-per-share growth and three-year annualized total return. Data for the list is provided by S&P Global Market Intelligence. The full list methodology can be found here.

About TIME’s America’s Growth Leaders 
TIME and Statista’s America’s Growth Leaders 2027 ranking recognizes U.S.-based public companies that achieved the highest compound annual revenue growth over a multi-year period. Rankings are determined by verified CAGR data, with additional factors like absolute revenue and employment growth used for context. More information can be found here.

About GigaCloud Technology Inc
GigaCloud Technology Inc is a pioneer of global end-to-end B2B technology solutions for large parcel merchandise. The Company’s B2B ecommerce platform, which it refers to as the “GigaCloud Marketplace,” integrates everything from discovery and payments to logistics tools into one easy-to-use platform. The Company’s global marketplace seamlessly connects manufacturers, primarily in Asia, with resellers, primarily in the U.S., Asia and Europe, to execute cross-border transactions with confidence, speed and efficiency. The Company offers a truly comprehensive solution that transports products from the manufacturer’s warehouse to the end customer’s doorstep, all at one fixed price. The Company first launched its marketplace in January 2019 by focusing on the global furniture market and has since expanded into additional categories such as home appliances and fitness equipment. For more information, please visit the Company’s website: https://investors.gigacloudtech.com/.

For investor and media inquiries, please contact:

GigaCloud Technology Inc
Investor Relations – ir@gigacloudtech.com

PondelWilkinson Inc.
Todd Kehrli (Investors) – tkehrli@pondel.com
Laurie Berman (Investors) – lberman@pondel.com
George Medici (Media) – gmedici@pondel.com

• HERO trial terminated early (67 of 90 planned participants randomized); all efficacy data are considered exploratory
• HQ-CT scores fell by Week 2 of dose escalation on ARD-101 and returned to near baseline within two weeks of stopping treatment, with less rebound on placebo
• OLE participants switching from placebo to ARD-101 saw a further reduction in HQ-CT scores by Day 28
• ARD-101 was well tolerated; most adverse events mild to moderate
• FDA lifted full clinical hold on ARD-101; Company plans to request FDA meeting to align on new Phase 3 trial design and expects to resume PWS clinical activities in 2027
• Conference call and webcast today at 8:00 a.m. ET

SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE) — Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi syndrome (PWS) and metabolic diseases, today reported exploratory efficacy data from its previously terminated Phase 3 Hunger Elimination or Reduction Objective (HERO) trial and open-label extension (OLE) trial. As previously announced, Aardvark unblinded the data accumulated across both the HERO trial and OLE trial to assess the totality of available efficacy and safety data to inform the path forward for ARD-101.

“Though the HERO trial was stopped early and the current partial data are not sufficient to draw definitive conclusions, we believe these exploratory efficacy and safety data are directionally consistent and give us confidence in the continued development of ARD-101 for the treatment of PWS. We look forward to continuing to work closely with the FDA and plan to request a meeting to align on the design of a new Phase 3 trial intended to support a future marketing application, with the important goal of delivering this potential treatment option to patients in need,” said Tien Lee, M.D., Founder and Chief Executive Officer of Aardvark. “Hyperphagia is one of the most challenging aspects of PWS for patients and their families, and we believe there remains a significant need for additional treatment options that can meaningfully reduce the constant, life-limiting hunger that defines this disease.”

A summary of the available dataset from the Phase 3 HERO trial and OLE trial can be found below. The HERO trial randomized 67 of the planned 90 participants and was terminated early. As such, all efficacy data are considered exploratory.

• At week two of dose escalation on ARD-101, a modest reduction in Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score versus placebo was observed in the HERO trial.
• Upon discontinuation of ARD-101, the average HQ-CT score of the ARD-101 treatment group returned to near baseline, while the placebo-treated group had less rebound toward baseline.
• In the OLE cohort, participants who switched from placebo to ARD-101 had an observed average reduction of 6 points in HQ-CT score.
• A similar pattern was observed for caregiver and clinician outcome measures, assessed by Caregiver Global Impression and Clinician Global Impression Severity scores, respectively.​
• ARD-101 was generally well tolerated, with most adverse events being mild to moderate.
• One cardiac serious adverse event was observed in the HERO trial at 800 mg twice daily (BID) in a participant who was also taking pitolisant, a CYP2D6 substrate. The U.S. Food and Drug Administration (FDA) concurred that this event is related to a drug-drug interaction.

Aardvark plans to resume dosing of ARD-101 in patients with PWS at a dose lower than the 800 mg BID dose studied in the Phase 3 HERO trial and OLE trial, pending discussion with the FDA. The Company plans to request a meeting with the FDA to align on its Phase 3 program, with the goal of advancing ARD-101 toward potential regulatory approval.

As previously announced on October 22, 2026, the FDA has lifted the clinical hold on the Company’s Investigational New Drug application for ARD-101 for the treatment of hyperphagia in PWS.

Conference Call and Webcast

The Company will host a live conference call and webcast for investors to discuss data from the HERO and OLE trials today, October 23, 2026, at 8:00 a.m. ET. To access the live webcast, participants may register here. To access the subsequent archived recording of this event, please visit the Investors section of Aardvark’s website.

About ARD-101

ARD-101 is an oral, small-molecule therapeutic designed to stimulate the release of gut-peptide hormones through activation of bitter taste receptors. ARD-101 is being developed as a treatment for hyperphagia associated with Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable hunger.

About Aardvark Therapeutics, Inc.

Aardvark is a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi Syndrome and metabolic diseases. Hunger, which is the discomfort from not having eaten recently, is a distinct neural signaling pathway separate from appetite, the reward-seeking desire for food. Our programs explore therapeutic applications in hunger-associated indications and potential complementary uses with anti-appetite therapies. For more information, visit www.aardvarktherapeutics.com.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements concerning: Aardvark’s business strategy, product candidates, the path forward for ARD-101, including the anticipated resumption of dosing of ARD-101 in patients with PWS and anticipated doses to be used in future trials, the timing for resuming clinical activities, and Aardvark’s planned engagement with the FDA regarding its Phase 3 program and the potential for any future Phase 3 trial to support a future marketing application or regulatory approval, as well as plans and objectives of management for future operations. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the risk that the FDA may not agree with Aardvark’s proposed Phase 3 program or may require additional studies; the timing of resuming dosing and activating clinical sites; the risk of additional safety findings, including risks related to cardiac safety and drug-drug interactions; limitations in interpreting data from the HERO trial and its OLE trial, which were terminated early and were not powered to assess efficacy; the risk of unfavorable clinical trial results; the risk that results from earlier clinical trials and preclinical studies may not necessarily be predictive of future results; the risk that Aardvark may use its capital resources sooner than expected; and other risks and uncertainties, including the factors described under the “Risk Factors” section of Aardvark’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission on August 11, 2026. When evaluating Aardvark’s business and prospects, careful consideration should be given to these risks and uncertainties. Any forward-looking statements contained in this press release are based on the current expectations of Aardvark’s management team and speak only as of the date hereof, and Aardvark specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, unless required by law.

Investor and Media Contact
Argot Partners
(212) 600-1902
Aardvark@Argotpartners.com

MONTVALE, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) — Balchem Corporation (NASDAQ: BCPC) today reported financial results for its 2026 fiscal third quarter ended September 30, 2026. For the quarter, the Company reported net sales of $290.7 million, net earnings of $46.7 million, adjusted EBITDA^(a) of $80.3 million, and free cash flow^(a) of $57.9 million.

Ted Harris, Chairman, President and CEO of Balchem, said, “Balchem delivered another excellent quarter, with healthy growth across all three of our reporting segments and record consolidated quarterly net sales, net earnings, and adjusted EBITDA.”

Third Quarter 2026 Financial Highlights:

• Net sales were $290.7 million, an increase of 8.6% from the prior year quarter.
• GAAP net earnings were $46.7 million, an increase of 16.0% from the prior year quarter.
• Adjusted EBITDA was $80.3 million, an increase of 12.4% from the prior year quarter.
• GAAP earnings per share were $1.46 compared to $1.24 in the prior year quarter and adjusted earnings per share^(a) were $1.57 compared to $1.35 in the prior year quarter.
• Cash flows from operations were $69.8 million, with free cash flow of $57.9 million.
• Sales and earnings from operations growth in all three of our reporting segments.

Recent Highlights:

• At the upcoming SupplySide Global trade show, we will showcase several of our latest Human Nutrition and Health technologies and innovations, including new science supporting VitaCholine^®, K2VITAL^™, Optifolin+^® and OptiMSM^®, as well as advances in performance nutrition and functional food and beverage applications. These innovations highlight the strength of our pipeline and our continued focus on developing differentiated, science-backed solutions that address important human health and wellness trends.
• Balchem repurchased approximately $28 million of common stock during the third quarter and approximately $127 million over the trailing twelve months, reflecting the Company’s balanced capital allocation strategy and commitment to long-term shareholder value creation.

Mr. Harris added, “With strong results through the first nine months of the year and a healthy balance sheet, Balchem is well positioned to continue executing our strategic growth initiatives, and we remain excited about the future of our company.”

Results for Period EndedSeptember 30, 2026 (unaudited) (Dollars in thousands, except per share data)
		Three Months Ended September 30,								Nine Months Ended September 30,
			2026				2025				2026				2025
Net sales		$	290,658			$	267,558			$	845,364			$	773,544
Gross margin			105,714				95,453				310,481				276,734
Operating expenses			43,277				40,874				133,197				119,698
Earnings from operations			62,437				54,579				177,284				157,036
Interest and other expenses			2,393				2,535				6,937				8,041
Earnings before income tax expense			60,044				52,044				170,347				148,995
Income tax expense			13,316				11,755				38,719				33,375
Net earnings		$	46,728			$	40,289			$	131,628			$	115,620
Diluted net earnings per common share		$	1.46			$	1.24			$	4.09			$	3.54
Adjusted EBITDA (a)		$	80,297			$	71,447			$	232,522			$	206,961
Adjusted net earnings (a)		$	50,350			$	43,982			$	141,437			$	125,560
Adjusted net earnings per common share (a)		$	1.57			$	1.35			$	4.40			$	3.84
Shares used in the calculations of diluted and adjusted net earnings per common share			32,032				32,595				32,181				32,702

(a)	See “Non-GAAP Financial Information” for a reconciliation of GAAP and non-GAAP financial measures.

Financial Results for the Third Quarter of 2026:

The Human Nutrition and Health segment generated record quarterly sales of $188.2 million, an increase of $14.1 million, or 8.1%, compared to the prior year quarter. The increase was driven by higher sales within both the nutrients business and the food ingredients and solutions businesses. Record earnings from operations for this segment of $45.6 million increased $4.8 million, or 11.8%, compared to $40.8 million in the prior year quarter, primarily due to the aforementioned higher sales and favorable mix, partially offset by higher operating expenses. Excluding the effect of non-cash expense associated with amortization of acquired intangible assets and other adjustments, record adjusted earnings from operations^(a) for this segment were $48.9 million, compared to $44.1 million in the prior year quarter, an increase of 10.9%.

The Animal Nutrition and Health segment generated quarterly sales of $63.0 million, an increase of $6.6 million, or 11.7%, compared to the prior year quarter. The increase was driven by higher sales in both the monogastric and ruminant species markets. Third quarter earnings from operations for this segment of $6.8 million increased $3.1 million, or 82.8%, compared to $3.7 million in the prior year quarter, primarily due to the aforementioned higher sales and favorable mix, partially offset by certain higher manufacturing input costs. Excluding the effect of non-cash expense associated with amortization of acquired intangible assets and other adjustments, adjusted earnings from operations for this segment were $7.0 million compared to $4.0 million in the prior year quarter, an increase of 73.6%.

The Specialty Products segment generated quarterly sales of $37.3 million, an increase of $1.6 million, or 4.5%, compared to the prior year quarter, due to higher sales in the performance gases business. Earnings from operations for this segment of $12.3 million increased $0.8 million, or 6.6%, compared to $11.5 million in the prior year quarter, primarily driven by the aforementioned higher sales and favorable mix, partially offset by higher operating expenses. Excluding the effect of non-cash expense associated with amortization of acquired intangible assets and other adjustments, adjusted earnings from operations for this segment were $13.1 million, compared to $12.7 million in the prior year quarter, an increase of 3.0%.

Consolidated quarterly gross margin of $105.7 million increased by $10.3 million, or 10.7%, compared to $95.5 million for the prior year comparable period. Gross margin as a percentage of sales was 36.4% compared to 35.7% in the prior year period, an increase of 70 basis points, primarily due to sales growth, favorable mix and manufacturing efficiencies, partially offset by certain higher manufacturing input costs. Operating expenses of $43.3 million for the quarter increased $2.4 million from the prior year comparable quarter, primarily due to higher compensation-related costs, partially offset by the net favorable impact of certain discrete items.

Net interest expense was $1.9 million and $2.6 million in the third quarters of 2026 and 2025, respectively. The decrease in interest expense was primarily due to lower outstanding borrowings and lower interest rates. Our effective tax rates for the three months ended September 30, 2026 and 2025 were 22.2% and 22.6%, respectively. The decrease in the effective tax rate was primarily due to higher favorable adjustments related to the filing of the prior year federal tax return and a higher foreign-derived intangible income deduction benefit, partially offset by an increase in certain state taxes.

Third quarter cash flows provided by operating activities were $69.8 million and free cash flow was $57.9 million. Net working capital of $240.8 million as of September 30, 2026 included a cash balance of $66.3 million. Significant cash payments during the quarter included net debt payments of $28.0 million, income taxes paid of $27.8 million, repurchases of common stock of $27.4 million, and capital expenditures and intangible assets acquired of $12.5 million. Outstanding debt on our revolving loan was $124.0 million as of September 30, 2026 and our net debt ^(b) was $57.7 million, with an overall leverage ratio ^(c) on a net debt basis of 0.2 times.

Mr. Harris said, “The Balchem team delivered another strong quarter in Q3 of 2026, and we remain confident in the long-term growth outlook for our company as we continue to execute our strategic growth initiatives.”

(b)	Net debt is defined as the outstanding balance on our revolving loan less cash and cash equivalents.
(c)	Leverage ratio is defined as net debt divided by trailing twelve months adjusted EBITDA.

Quarterly Conference Call

A quarterly conference call will be held on Friday, October 23, 2026, at 11:00 AM Eastern Time (ET) to review third quarter 2026 results. Ted Harris, Chairman, President and CEO and Martin Bengtsson, CFO, will host the call. Institutional investors, analysts and other members of the financial community are invited to join the live call by dialing +1-833-461-5787 (USA/Canada toll free) or +1-585-542-9983 (International Toll), and referencing Meeting ID: 831870284, five minutes prior to the scheduled start time of the conference call. Investors and the public are invited to listen to the live webcast at https://events.q4inc.com/attendee/831870284. The conference call will be available for replay shortly after the conclusion of the call at https://events.q4inc.com/attendee/831870284 for one year.

Segment Information

Balchem Corporation reports three business segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition and Health segment delivers customized food and beverage ingredient systems, as well as key nutrients into a variety of applications across the food, supplement and pharmaceutical industries. The Animal Nutrition and Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged performance gases for use in healthcare and other industries, and also provides chelated minerals to the micronutrient agricultural market. Sales and production of products outside of our reportable segments and other minor business activities are included in “Other and Unallocated”.

Forward-Looking Statements

This release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, which reflect our expectation or belief concerning future events that involve risks and uncertainties. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “forecast,” “outlook,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” or the negative thereof or variations thereon or similar expressions generally intended to identify forward-looking statements. Forward-looking statements may relate to such matters as projections of revenue, margins, expenses, tax provisions, earnings, cash flows, benefit obligations, dividends, share repurchases or other financial items; any statements of the plans, strategies and objectives of management for future operations, including those relating to any statements concerning expected development, performance or market share relating to our products and services; any statements regarding future economic conditions or our performance; any statements regarding pending investigations, claims or disputes; any statements of expectation or belief; and any statements of assumptions underlying any of the foregoing. These statements are based on the Company’s currently available information and our current assumptions, expectations and projections about future events. They are subject to future events, risks and uncertainties – many of which are beyond the Company’s control – as well as potentially inaccurate assumptions, that could cause actual results to differ materially from those in the forward-looking statements. Important factors and other risks that may affect the Company’s business or that could cause actual results to differ materially are included in filings the Company makes with the U.S. Securities and Exchange Commission from time to time, including its Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, its Current Reports on Form 8-K, and in its other SEC filings. Reference should be made to such factors and all forward-looking statements are qualified in their entirety by the above cautionary statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact: Jacqueline Yarmolowicz, Balchem Corporation (Telephone: 845-326-5600)

Selected Financial Data (unaudited)
($ in 000’s)

Business Segment Net Sales:		Three Months Ended September 30,								Nine Months Ended September 30,
			2026				2025				2026				2025
Human Nutrition and Health		$	188,227			$	174,088			$	536,749			$	493,318
Animal Nutrition and Health			62,990				56,376				189,633				169,681
Specialty Products			37,294				35,683				112,532				106,143
Other (d)			2,147				1,411				6,450				4,402
Total		$	290,658			$	267,558			$	845,364			$	773,544
(d) Other consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation.

Business Segment Earnings Before Income Taxes:		Three Months Ended September 30,								Nine Months Ended September 30,
			2026				2025				2026				2025
Human Nutrition and Health		$	45,633			$	40,831			$	128,034			$	117,147
Animal Nutrition and Health			6,789				3,713				17,708				12,463
Specialty Products			12,301				11,534				37,129				32,388
Other and Unallocated (e)			(2,286	)			(1,499	)			(5,587	)			(4,962	)
Interest and other expenses			(2,393	)			(2,535	)			(6,937	)			(8,041	)
Total		$	60,044			$	52,044			$	170,347			$	148,995
(e) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of transaction and integration costs of $578 and $1,495 for the three and nine months ended September 30, 2026, respectively, and $333 and $1,227 for the three and nine months ended September 30, 2025, respectively.

Selected Balance Sheet Items
(Dollars in thousands)		September 30, 2026				December 31, 2025
		(unaudited)
Cash and cash equivalents		$	66,264			$	74,570
Accounts receivable, net			145,635				143,596
Inventories			177,006				131,449
Other current assets			15,972				15,999
Total current assets			404,877				365,614
Property, plant and equipment, net			306,135				306,648
Goodwill			807,487				816,375
Intangible assets with finite lives, net			147,366				163,289
Right of use assets			17,683				16,192
Other assets			20,024				18,134
Total non-current assets			1,298,695				1,320,638
Total assets		$	1,703,572			$	1,686,252
Current liabilities		$	164,115			$	176,384
Revolving loan			124,000				164,000
Deferred income taxes			52,273				54,143
Other long-term obligations			36,407				34,312
Total liabilities			376,795				428,839
Stockholders’ equity			1,326,777				1,257,413
Total liabilities and stockholders’ equity		$	1,703,572			$	1,686,252

Balchem Corporation Condensed Consolidated Statements of Cash Flows (Dollars in thousands)
(unaudited)
		Nine Months Ended September 30,
			2026				2025
Cash flows from operating activities:
Net earnings		$	131,628			$	115,620
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization			37,100				33,969
Stock compensation expense			16,316				14,298
Other adjustments			3,037				(1,692	)
Changes in assets and liabilities			(31,537	)			(12,914	)
Net cash provided by operating activities			156,544				149,281
Cash flows from investing activities:
Capital expenditures and intangible assets acquired			(29,605	)			(27,275	)
Cash paid for acquisitions, net of cash acquired			—				(323	)
Proceeds from the sale of assets			7				267
Investment in affiliates			(155	)			(144	)
Net cash used in investing activities			(29,753	)			(27,475	)
Cash flows from financing activities:
Proceeds from revolving loan			88,000				70,000
Principal payments on revolving loan			(128,000	)			(106,000	)
Principal payments on finance leases			(153	)			(145	)
Cash paid for financing costs			(1,943	)			—
Proceeds from stock options exercised			11,589				6,867
Dividends paid			(30,773	)			(28,276	)
Repurchases of common stock			(71,925	)			(54,008	)
Net cash used in financing activities			(133,205	)			(111,562	)
Effect of exchange rate changes on cash			(1,892	)			5,334
(Decrease) increase in cash and cash equivalents			(8,306	)			15,578
Cash and cash equivalents, beginning of period			74,570				49,515
Cash and cash equivalents, end of period		$	66,264			$	65,093

Non-GAAP Financial Information

In addition to disclosing financial results in accordance with United States (U.S.) generally accepted accounting principles (GAAP), this earnings release contains non-GAAP financial measures that we believe are helpful in understanding and comparing our past financial performance and our future results. The non-GAAP financial measures in this press release include adjusted gross margin, adjusted earnings from operations, adjusted net earnings and the related adjusted diluted per share amounts, EBITDA, adjusted EBITDA, adjusted income tax expense, free cash flow, net debt, and leverage ratio. The non-GAAP financial measures disclosed by the Company exclude certain business combination accounting adjustments and certain other items related to acquisitions, certain equity compensation, nonqualified deferred compensation plan expense (income), and certain one-time or unusual transactions. Detailed non-GAAP adjustments are described in the reconciliation tables below and also explained in the related footnotes. These non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations from these results should be carefully evaluated. Investors should not consider non-GAAP measures as alternatives to the related GAAP measures.

Set forth below are reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.

Table 1
(unaudited)

Reconciliation of Non-GAAP Measures to GAAP (Dollars in thousands, except per share data)
		Three Months Ended September 30,								Nine Months Ended September 30,
			2026				2025				2026				2025
Reconciliation of adjusted gross margin
GAAP gross margin		$	105,714			$	95,453			$	310,481			$	276,734
Amortization of intangible assets and finance leases (1)			715				739				2,162				2,156
Adjusted gross margin		$	106,429			$	96,192			$	312,643			$	278,890
Reconciliation of adjusted earnings from operations
GAAP earnings from operations		$	62,437			$	54,579			$	177,284			$	157,036
Amortization of intangible assets and finance leases (1)			4,333				4,394				13,137				12,819
Transaction and integration costs (2)			578				333				1,495				1,227
Nonqualified deferred compensation plan expense (3)			(45	)			404				572				839
Restructuring costs (4)			—				—				—				(192	)
Adjusted earnings from operations		$	67,303			$	59,710			$	192,488			$	171,729
Reconciliation of adjusted net earnings
GAAP net earnings		$	46,728			$	40,289			$	131,628			$	115,620
Amortization of intangible assets and finance leases (1)			4,433				4,467				13,381				13,035
Transaction and integration costs (2)			578				333				1,495				1,227
Restructuring costs (4)			—				—				—				(192	)
Income tax adjustment (5)			(1,389	)			(1,107	)			(5,067	)			(4,130	)
Adjusted net earnings		$	50,350			$	43,982			$	141,437			$	125,560
Adjusted net earnings per common share – diluted		$	1.57			$	1.35			$	4.40			$	3.84

Table 2 
(unaudited)

Reconciliation of GAAP Net Earnings to EBITDA and to Adjusted EBITDA (Dollars in thousands)
		Three Months Ended September 30,								Nine Months Ended September 30,
			2026				2025				2026				2025
Net earnings – as reported		$	46,728			$	40,289			$	131,628			$	115,620
Add back:
Provision for income taxes			13,316				11,755				38,719				33,375
Interest and other expenses			2,393				2,535				6,937				8,041
Depreciation and amortization			12,288				11,481				36,855				33,753
EBITDA			74,725				66,060				214,139				190,789
Add back:
Non-cash compensation expense related to equity awards			5,039				4,650				16,316				14,298
Transaction and integration costs (2)			578				333				1,495				1,227
Nonqualified deferred compensation plan expense (3)			(45	)			404				572				839
Restructuring costs (4)			—				—				—				(192	)
Adjusted EBITDA		$	80,297			$	71,447			$	232,522			$	206,961

Table 3
(unaudited)

Reconciliation of GAAP Effective Income Tax Rate to Non-GAAP Effective Income Tax Rate (Dollars in thousands)
		Three Months Ended September 30,
			2026			Effective Tax Rate				2025			Effective Tax Rate
GAAP Income Tax Expense		$	13,316			22.2	%		$	11,755			22.6	%
Impact of ASU 2016-09 (6)			260							21
Adjusted Income Tax Expense		$	13,576			22.6	%		$	11,776			22.6	%

		Nine Months Ended September 30,
			2026			Effective Tax Rate				2025			Effective Tax Rate
GAAP Income Tax Expense		$	38,719			22.7	%		$	33,375			22.4	%
Impact of ASU 2016-09 (6)			1,550							894
Adjusted Income Tax Expense		$	40,269			23.6	%		$	34,269			23.0	%

Table 4
(unaudited)

Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow (Dollars in thousands)
		Three Months Ended September 30,								Nine Months Ended September 30,
			2026				2025				2026				2025
Net cash provided by operating activities		$	69,772			$	65,572			$	156,544			$	149,281
Capital expenditures and proceeds from the sale of assets			(11,863	)			(14,891	)			(28,559	)			(26,866	)
Free cash flow		$	57,909			$	50,681			$	127,985			$	122,415

(1) Amortization of intangible assets and finance leases: Amortization of intangible assets and finance leases consists of amortization of customer relationships, trademarks and trade names, developed technology, regulatory registration costs, patents and trade secrets, capitalized loan issuance costs, other intangibles acquired primarily in connection with business combinations, and finance leases. We record expense relating to the amortization of these intangibles and finance leases in our GAAP financial statements. Amortization expenses for our intangible assets and finance leases are inconsistent in amount and are significantly impacted by the timing and valuation of acquisitions. Consequently, our non-GAAP adjustments exclude these expenses to facilitate an evaluation of our current operating performance and comparisons to our past operating performance.

(2) Transaction and integration costs: Transaction and integration costs related to acquisitions and divestitures are expensed in our GAAP financial statements. Management excludes these items for the purposes of calculating adjusted EBITDA and other non-GAAP financial measures. We believe that excluding these items from our non-GAAP financial measures is useful to investors because these are items associated with transactions that are inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult.

(3) Nonqualified deferred compensation plan (income) expense: Gains and losses on rabbi trust assets related to our nonqualified deferred compensation plan are recorded in other (income) expense while the offsetting increases or decreases to the deferred compensation liability are recorded within earnings from operations. The increases and decreases in the deferred compensation liability are driven by market volatility and are not a true reflection of company performance. We believe excluding these amounts from our non-GAAP financial measures is useful to investors because these items are inconsistent in amount based on market conditions causing comparison of current and historical financial results to be difficult.

(4) Restructuring costs: Restructuring costs related to a reorganization of the business are recorded in our GAAP financial statements. Management excludes these items for the purposes of calculating adjusted EBITDA and other non-GAAP financial measures. We believe that excluding these items from our non-GAAP financial measures is useful to investors because these items are inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult.

(5) Income tax adjustment: For purposes of calculating adjusted net earnings and adjusted diluted earnings per share, we adjust the provision for (benefit from) income taxes to tax effect the taxable and deductible non-GAAP adjustments described above as they have a significant impact on our income tax (benefit) provision. Additionally, the income tax adjustment is adjusted for the impact of adopting ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting” and uses our non-GAAP effective rate applied to both our GAAP earnings before income tax expense and non-GAAP adjustments described above. See Table 3 for the calculation of our non-GAAP effective tax rate.

(6) Impact of ASU 2016-09: The primary impact of ASU No. 2016-09, “Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”), was the recognition during the three and nine months ended September 30, 2026 and 2025, of excess tax benefits as a reduction to the provision for income taxes and the classification of these excess tax benefits in operating activities in the consolidated statement of cash flows instead of financing activities. Management excludes this item for the purpose of calculating adjusted Income Tax Expense. We believe that excluding the item in our non-GAAP financial measures is useful to investors because it is inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult.

January 5, 2027 payment date following December 8, 2026 record date

TORONTO, Oct. 23, 2026 (GLOBE NEWSWIRE) — Rogers Communications Inc. (TSX: RCI.A and RCI.B) (NYSE: RCI) (“Rogers”) announced that its Board of Directors (the “Board”) declared a quarterly dividend totaling 50 cents per share (the “Quarterly Dividend”) on each of its outstanding Class B Non-Voting shares and Class A Voting shares.
           
The declared Quarterly Dividend will be paid January 5, 2027 to shareholders of record on December 8, 2026. Such quarterly dividends are only payable as and when declared by the Board and there is no entitlement to any dividend prior thereto.

About Rogers Communications Inc:
Rogers is Canada’s communications, sports and entertainment company and its shares are publicly traded on the Toronto Stock Exchange (TSX: RCI.A and RCI.B) and on the New York Stock Exchange (NYSE: RCI). For more information, please visit rogers.com or about.rogers.com/investor-relations.

For further information:
Investor Relations
1-844-801-4792
investor.relations@rci.rogers.com

Agent Email is purpose-built infrastructure that lets AI agents receive, understand, and answer inbound email at scale—keeping replies threaded in Gmail and Outlook, grounding answers in a company’s private knowledge base, and writing intent signals back into CRM.

SINGAPORE, Oct. 23, 2026 (GLOBE NEWSWIRE) — Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services, today announced Agent Email, AI-powered infrastructure for its AI-first customer engagement platform EngageLab that lets AI agents receive, understand, and answer inbound customer email at scale. Technical and growth teams can now deploy AI agents that automatically receive customer replies, respond with full conversation context, and write qualified intent signals back into CRM systems.

Most AI email tools on the market address only the first step of the email lifecycle: writing a message. What happens after send—deliverability, inbound replies, intent detection, and follow-up—remains largely manual. EngageLab’s Agent Email is purpose-built to close that post-send gap.

Agent Email provides the “receive, send, and manage” infrastructure purpose-built for AI agents. When a recipient replies to a campaign or automated message, the inbound gateway captures the message, converts it into structured text an agent can read, and threads multi-turn conversations using the standard Message-ID, In-Reply-To, and References email headers—so replies stay folded into the original conversation in Gmail and Outlook. Agents can ground answers in a company’s private knowledge base and push structured summaries and intent signals into CRM. Agent Email supports both a high-reputation shared sending domain for teams without DNS/SPF/DKIM/DMARC resources and custom domains, with a smooth upgrade path between the two. It is natively compatible with leading AI developer tools including Codex, Cursor, Claude Code, OpenClaw, and Hermes.

“Email value does not end at the send button. Our goal is to make sure every customer reply is understood and answered, turning one-way campaigns into conversations that actually move revenue,” said Mr. Weidong Luo, Chairman and Chief Executive Officer of Aurora Mobile.

EngageLab positions the capabilities for three immediate use cases: closing the reply loop on lifecycle messages such as welcome, renewal, and cart-recovery emails; zero-config cold-start outreach for companies entering overseas markets using the shared domain; and 24/7 cross-time-zone technical and sales response grounded in internal documentation.

Availability note: Agent Email is available now to enterprise customers. For access, contact EngageLab or visit engagelab.com.

About EngageLab
EngageLab is an AI-first customer engagement platform that helps you build stronger customer relationships with AI agents, unified customer data, and reliable delivery across channels.

EngageLab’s global customers include Dhgate, HelloRide, The Consejo Nacional Electoral (CNE) of Ecuador, J&T Cargo, Blurams and many more.

For more information, please contact: marketing@engagelab.com

About Aurora Mobile Limited
Founded in 2011, Aurora Mobile (NASDAQ: JG) is a leading provider of customer engagement and marketing technology services. The Company is dedicated to empowering global enterprises with stable, efficient, and intelligent customer interaction solutions. Leveraging its first-mover advantage in mobile messaging, Aurora Mobile has evolved into a comprehensive platform that integrates Omnichannel Engagement, AI-Driven Marketing, Advanced AI Customer Support, and Frictionless Identity Security. Through its flagship brand EngageLab and its robust AI infrastructure GPTBots.ai, the Company helps businesses achieve seamless customer reach, automate complex marketing journeys, and optimize service efficiency with AI agents, accelerating digital transformation for clients worldwide.

For more information, please visit: https://ir.aurora-mobile.com/

Media contact: marketing@aurora-mobile.com

Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, the Business Outlook and quotations from management in this announcement, as well as Aurora Mobile’s strategic and operational plans, contain forward-looking statements. Aurora Mobile may also make written or oral forward-looking statements in its reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about Aurora Mobile’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Aurora Mobile’s strategies; Aurora Mobile’s future business development, financial condition and results of operations; Aurora Mobile’s ability to attract and retain customers; its ability to develop and effectively market data solutions, and penetrate the existing market for developer services; its ability to transition to the new advertising-driven SAAS business model; its ability to maintain or enhance its brand; the competition with current or future competitors; its ability to continue to gain access to mobile data in the future; the laws and regulations relating to data privacy and protection; general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company’s filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and Aurora Mobile undertakes no duty to update such information, except as required under applicable law.

For more information, please contact:
Aurora Mobile Limited
E-mail: ir@aurora-mobile.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0d480788-8c4b-4032-9754-039f6fc7f94d